Literature DB >> 15471835

Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline.

Johannes Schwarz1, Alexander Storch, Walter Koch, Oliver Pogarell, Perry E Radau, Klaus Tatsch.   

Abstract

UNLABELLED: Imaging of L-dopa uptake or dopamine transporter binding can monitor the progression of Parkinson's disease. Most follow-up studies have provided data best fitted by a linear decline of their outcome measure. However, in these studies, patients were repeatedly scanned during their first years after a diagnosis had been established.
METHODS: We followed 6 patients with early Parkinson's disease for 7.5 y using 123I-labeled N-(3-iodopropene-2-yl)-2beta-carbomethoxy-3beta-(4-chlorophenyl) tropane and SPECT.
RESULTS: Loss of dopamine transporter binding was best fitted using a single exponential approximation. A 63% loss (tau [time constant tau]) was calculated as 5.18 +/- 7.62 y in the putamen and 10.62 +/- 31.4 y in the caudate nucleus when a 3-parameter fit was used.
CONCLUSION: These data approximate, for what is to our knowledge the first time, the decline of dopamine transporter binding as expected in biologic systems and may allow for models that correct for exponential decline to be developed and for disease-modifying effects in patients with advanced disease to be determined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471835

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  19 in total

1.  Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up.

Authors:  Swen Hesse; Karl Strecker; Dirk Winkler; Julia Luthardt; Christoph Scherfler; Annegret Reupert; Christian Oehlwein; Henryk Barthel; Jens-Peter Schneider; Florian Wegner; Philipp Meyer; Jürgen Meixensberger; Osama Sabri; Johannes Schwarz
Journal:  J Neurol       Date:  2008-05-02       Impact factor: 4.849

2.  Granulocyte-Colony Stimulating Factor Alters the Pharmacodynamic Properties of Cocaine in Female Mice.

Authors:  Lillian J Brady; Rebecca S Hofford; Jennifer Tat; Erin S Calipari; Drew D Kiraly
Journal:  ACS Chem Neurosci       Date:  2019-09-11       Impact factor: 4.418

3.  Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients.

Authors:  Gesine Paul; Olof Zachrisson; Andrea Varrone; Per Almqvist; Markus Jerling; Göran Lind; Stig Rehncrona; Bengt Linderoth; Hjalmar Bjartmarz; Lisa L Shafer; Robert Coffey; Mikael Svensson; Katarina Jansson Mercer; Anton Forsberg; Christer Halldin; Per Svenningsson; Håkan Widner; Jonas Frisén; Sven Pålhagen; Anders Haegerstrand
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808

4.  Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes.

Authors:  Nathalie L Albert; Marcus Unterrainer; Markus Diemling; Guoming Xiong; Peter Bartenstein; Walter Koch; Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; L Özlem Atay Kapucu; Andreas Kluge; Morten Ziebell; Jacques Darcourt; Flavio Nobili; Marco Pagani; Osama Sabri; Swen Hesse; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-18       Impact factor: 9.236

5.  Profound midbrain atrophy in patients with Wilson's disease and neurological symptoms?

Authors:  K Strecker; J P Schneider; H Barthel; W Hermann; F Wegner; A Wagner; J Schwarz; O Sabri; C Zimmer
Journal:  J Neurol       Date:  2006-04-10       Impact factor: 4.849

6.  Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts.

Authors:  Oliver Pogarell; Walter Koch; Franz J Gildehaus; Andreas Kupsch; Olle Lindvall; Wolfgang H Oertel; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-27       Impact factor: 9.236

7.  Robust, fully automatic delineation of the head contour by stereotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy.

Authors:  Catharina Lange; Jens Kurth; Anita Seese; Sarah Schwarzenböck; Karen Steinhoff; Bert Umland-Seidler; Bernd J Krause; Winfried Brenner; Osama Sabri; Swen Hesse; Ralph Buchert
Journal:  Eur Radiol       Date:  2015-02-26       Impact factor: 5.315

8.  Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.

Authors:  Guangwei Du; Mechelle M Lewis; Christopher Sica; Lu He; James R Connor; Lan Kong; Richard B Mailman; Xuemei Huang
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

9.  Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls.

Authors:  Walter Koch; Marcus Unterrainer; Guoming Xiong; Peter Bartenstein; Markus Diemling; Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Morten Ziebell; Jacques Darcourt; Flavio Nobili; Marco Pagani; Swen Hesse; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-08       Impact factor: 9.236

10.  Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.

Authors:  S Hesse; C Oehlwein; H Barthel; J Schwarz; D Polster; A Wagner; O Sabri
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.